Press Releases

Year

Nov 28 2016

Intec Pharma Enters into Agreement with the Michael J. Fox Foundation Around Its Phase III Trial Recruitment

JERUSALEM, November 28, 2016 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces it has entered into an agreement with the Michael J.

Nov 09 2016

Intec Pharma to Sponsor Investigator Meeting for Pivotal Phase III Study of Accordion Pill Carbidopa/Levodopa in Advanced Parkinson's Disease Patients

JERUSALEM, November 9, 2016 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, announces that the Company will be hosting an investigator meeting

Nov 07 2016

Intec Pharma Announces Protocol Amendment to Phase III Study of Accordion Pill Carbidopa/Levodopa in Advanced Parkinson's Disease Patients

Sample size reduced from 460 to 328 patients without altering the trial's objectives, endpoints or statistical powering JERUSALEM, November 7, 2016 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its

Oct 31 2016

Intec Pharma Granted Chinese Patent for Accordion PillTM Carbidopa / Levodopa

Strengthens protection for Intec Pharma's leading Parkinson's disease product currently in a global Phase III clinical trial Intec Pharma Ltd. (NASDAQ:NTEC) (TASE:INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform

Sep 07 2016

Intec Pharma to Participate in Upcoming September Conferences

Intec Pharma Ltd. (Nasdaq:NTEC), a late stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces that Company management will participate at the Rodman & Renshaw 18th Annual Global Investment Conference taking place from

Sep 06 2016

Intec Pharma Granted European Patent for Accordion Pill™–Carbidopa / Levodopa

Fortifies protection for Intec Pharma's leading product for Parkinson's disease currently in a global Phase III clinical trial Intec Pharma Ltd. (Nasdaq: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology,

Sep 01 2016

Intec Pharma Reports First Half 2016 Financial Results

Intec Pharma Ltd. (Nasdaq: NTEC), a late stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, reports financial results for the three and six months ended June 30, 2016. Highlights of the first six months of 2016 and recent weeks

Aug 04 2016

Intec Pharma to Pursue Development of Accordion Pill for Cannabinoid Therapies

Phase 1 clinical trial to begin in first quarter 2017 Intec Pharma Ltd. (Nasdaq:NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces the initiation of a new clinical development program for its

Jun 03 2016

Intec Pharma Announces Planned Management Changes

JERUSALEM, June 3, 2016 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC; TASE: INTP), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, announced today that Mr. Oren Mohar, the company's Chief Financial Officer, has

May 31 2016

Intec Pharma Receives Approval for US$5.2 Million Grant

JERUSALEM, May 31, 2016 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC; TASE: INTP), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary drug delivery platform technology, the Accordion Pill, announced today that the Israeli National Authority for

First page
Previous page
Page 1
Page 2
Page 3
Page 4
Page 5
Current page 6
Page 7
Page 8
Next page
Last page

Displaying 51 - 60 of 77